Clinical Trials for Pancreas Cancer

Phase I, Open-Label Study of Autologous Mutant KRAS and ILT4-Redirected T-cell Receptor Cells (TCR1188-ABC)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with HLA-A*11:01-positive, KRAS G12V-mutant metastatic pancreatic, biliary, colorectal, or non-small cell lung cancer after standard therapy receive fludarabine/cyclophosphamide lymphodepletion followed by a single infusion of autologous TCR-engineered T cells recognizing HLA-A*11:01-presented KRAS G12V and targeting ILT4/LILRB2-positive immunosuppressive cells; prophylactic tocilizumab is given on day 2.

ClinicalTrials.gov ID: NCT07594067

Phase 1/2 Study Of IL15-Transduced, TGFBR2 KO, TROP2 CAR- Engineered Cord Blood-Derived NK Cells Administered Intraperitoneally And Intravenously In Combination With Oral Belzutifan For The Management Of Pancreatic Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable recurrent, unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma or ampullary carcinoma progressing after FOLFIRINOX or gemcitabine-based therapy receive intraperitoneal and intravenous allogeneic cord-blood CAR-NK cells plus oral belzutifan. The CAR-NK cells are engineered with a TROP2-directed CAR (target requires protocol confirmation), IL-15 expression, and TGFBR2 knockout; belzutifan inhibits HIF-2α.

ClinicalTrials.gov ID: NCT07377526

A Phase 1 Theranostic Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of SKL35501, an Alpha-Emitting Radiopharmaceutical Targeting NTSR1, With SKL35502 as Companion Imaging Agent in Adult Patients With Selected Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed or refractory advanced pancreatic, colorectal, biliary tract, head and neck squamous cell, esophageal, or gastric cancer receive the NTSR1-targeted imaging agent SKL35502. Those with tumor uptake on imaging may receive SKL35501, an actinium-225–linked NTSR1-targeted radiopharmaceutical designed to deliver alpha radiation to tumor cells.

ClinicalTrials.gov ID: NCT07812805

Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination With Neratinib in Solid Tumors With HER2 Alterations

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated metastatic or unresectable HER2-overexpressing, ERBB2-amplified, or HER2-mutant solid tumors receive oral neratinib, an irreversible pan-HER kinase inhibitor, plus trastuzumab deruxtecan, a HER2-directed antibody–drug conjugate carrying a topoisomerase I inhibitor. Dose-expansion cohorts include nonpancreatic solid tumors and pancreatic adenocarcinoma.

ClinicalTrials.gov ID: NCT05372614

A Phase 1/2 Dose Escalation and Cohort Expansion Study of LP-184 in Patients with Advanced or Metastatic Solid Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors after standard therapy, or with no standard option, receive LP-184, a PTGR1-activated acylfulvene prodrug that alkylates DNA. Expansion cohorts include triple-negative breast, non-small cell lung, pancreatic, DNA damage repair–altered, and recurrent glioblastoma tumors; LP-184 is given alone or with olaparib in triple-negative breast cancer or spironolactone in recurrent glioblastoma.

ClinicalTrials.gov ID: NCT05933265

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors or lymphoma and no remaining standard or curative treatment option receive oral VMD-928 monotherapy. Patients generally require TrkA overexpression or an NTRK1 fusion; VMD-928 is an investigational allosteric TrkA/NTRK1 inhibitor.

ClinicalTrials.gov ID: NCT03556228

A Phase 1, Open-Label, Dose Escalation and Expansion Study of Mavrostobart (PT199) Administered Alone in Adult Patients with Advanced Solid TuMORs, in CombiNation with a Checkpoint INhibitor TreatinG Wild-type Non-Small Cell Lung Cancer, or in Combination with ChemoTherapy for Metastatic or Advanced PAncreatic Ductal AdenocaRcinoma (MORNINGSTAR)

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors, including NSCLC without actionable alterations and pancreatic ductal adenocarcinoma, receive investigational mavrostobart alone or with a PD-1 inhibitor and/or cohort-specific chemotherapy. Mavrostobart is an anti-CD73 antibody designed to reduce adenosine-mediated immune suppression.

ClinicalTrials.gov ID: NCT05431270

First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic solid tumors that have progressed after standard therapy receive oral metarrestin (ML-246); expansion cohorts include adults with pancreatic, colorectal, or breast cancer and adolescents with solid tumors other than rhabdomyosarcoma who have no standard treatment options. Metarrestin targets the perinucleolar compartment and may inhibit eEF1A2-associated RNA polymerase I activity.

ClinicalTrials.gov ID: NCT04222413

A Phase I/II, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients With Advanced Malignancies

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic cancer after progression on, intolerance of, or lack of benefit from standard therapy receive oral AMXI-5001 twice daily as monotherapy. AMXI-5001 is an investigational dual inhibitor of PARP1/2-mediated DNA repair and tubulin polymerization.

ClinicalTrials.gov ID: NCT04503265

A Phase Ia/Ib, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of RSC-1255 in Patients With Advanced Solid Tumor Malignancies

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors whose disease has progressed after standard therapy, or who are refractory to or unable to tolerate it, receive oral RSC-1255 twice daily as monotherapy. RSC-1255 is an investigational small molecule described as a pan-mutant and wild-type RAS inhibitor; preclinical work also identifies V-ATPase as a target, but its clinical mechanism and benefit remain unestablished.

ClinicalTrials.gov ID: NCT04678648